Drug firm Bafna Pharmaceuticals today said it has received UK health regulator's nod to manufacture Finasteride, used in the treatment of enlarged prostate gland.
The company has received approval from UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture Finasteride in the strength of 5 mg, Bafna Pharmaceuticals said in a statement.
"Bafna Pharma has been constantly upgrading its manufacturing facilities to efficiently meet the anticipated demands of the global markets," Bafna Pharmaceuticals CMD Mahaveer Chand Bafna said.
"The approval from UK MHRA for Finasteride 5 mg will enable Bafna Pharma to widen the customer base in Europe," he added.
Finasteride 5 mg tablet is a prescription-only medicine (POM) used for the treatment and control of benign prostatic hyperplasia in order to cause regression of an enlarged prostate and improvement of other symptoms.
The Finasteride nod is the company's 14th approval from UK MHRA, Bafna said.
Shares of Bafna Pharmaceuticals were trading at Rs 48 on Bombay Stock Exchange in late afternoon trade, up 2.02 per cent from its previous close.